

Best Available Copy

WO 03/032980 A1

up to two groups selected independently from C₁-alkyl, and the sum of m+n is from 0 to 4; p is selected from 0 and 1; q and s are selected from 0, 1 and 2; r is selected from 0, 1 and 2; or pharmaceutically acceptable salts or solvates thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



WO 03/032980 A1

(10) International Publication Number

(43) International Publication Date
24 April 2003 (24.04.2003)

PCT

(11) International Publication Number
WO 03/032980 A1

(51) International Patent Classification: A61K 31/140,
31/041, 31/047, 31/049, 31/045, 31/046, 31/026,
31/045, 31/075, C07D 21/06, 27/28, 29/12, 29/18,
30/14, 30/152, 23/06

(21) International Application Number: PCT/GB02/11573

(22) International Filing Date: 16 October 2002 (16.10.2002)

(23) Filing Language:

(26) Publication Language: English

(30) Priority Data:
01/240317, 17 October 2001 (17.10.2001) GB

(71) Applicant (for all designated States except US): GLAXO
GROUP LIMITED (GB/GB); Glaxo Wellcome House,
Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and
(73) Inventors/Applicants (for US only): ANCELL, Richard,
Mervyn (GB/GB); GlaxoSmithKline, Gurnells Wood
Road, Stevenage, Hertfordshire SG1 2NY (GB); ASTON,
Neil, Mary (GB/GB); GlaxoSmithKline, Gurnells Wood
Road, Stevenage, Hertfordshire SG1 2NY (GB); BAW,
BOROUGH, Paul (GB/GB); GlaxoSmithKline, Gurnells
Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).


(74) Agent: GLADWIN, Annada, Rachel; GlaxoSmithK-
line, CN0251, 380 Great West Road, Brentford, Middlesex
TW8 9GS (GB).

(81) Designated States (initially): AL, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, BE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KB, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PT, RO, RU, SD, SR, SG,
SI, SK, SL, TI, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (optional): AR, BO, FJ, GH, GM,
KL, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW,
Bahrain patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, IE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,

(Continued on next page)

(54) Title: 5'-CARBAMOYL-1,1'-BIPHENYL-4-CARBOXYAMIDE DERIVATIVES AND THEIR USE AS P38 KINASE INHIBITORS



(57) Abstract: Compounds of formula (1), wherein X is a bond or a phenyl group which may be optionally substituted; R¹ is selected from an optionally substituted five- to seven-membered heterocyclic ring, an optionally substituted five- to seven-membered heterocyclic ring and an optionally substituted fused bicyclic ring; R² is selected from hydrogen, C₁-alkyl and -(CH₂)₂-"alkenyl"; or when X is a bond and m+n are both zero R¹ and R², together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen and nitrogen, which can be optionally substituted by C₁-alkyl; R² is the group -CO-NH-(CH₂)₂-R³; U is selected from methyl and halogen; W is selected from methyl and chlorine; Y and Z are each selected independently from hydrogen, methyl and halogen; Z is selected from -O- and a bond; m and n are independently selected from 0, 1 and 2, wherein each carbon atom of the resulting carbon chain may be optionally substituted with

TR, OAPI patent (BH, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NL, SN, TD, TG),
For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

ning of each regular issue of the PCT Gazette.

Published:

— with international search report
before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

15R - 6

WO 03/032980 A1

wherein R¹, R², R³, m, n and X are as defined above, or a pharmaceutically acceptable salt or solvate thereof.

In a preferred embodiment, the molecular weight of a compound of formula (I) does not exceed 1000, more preferably 800, even more preferably 600.

5 The group R¹ may be optionally substituted by up to three substituents, more preferably one or two substituents, selected from C₁-alkyl, C₁-alkoxy, oxy, halogen, hydroxyC₁-alkyl, -N(C₁-alkyl)₂, -CH₂-NC₁-alkyl, -CO₂C₁-alkyl, phenyl optionally substituted by halogen and benzyl optionally substituted by halogen and/or cyano.

10 When X is phenyl, the optional substituents for X are selected independently from C₁-alkyl, C₁-alkoxy, halogen, trifluoromethyl, trifluoromethoxy, and cyano. Particularly preferred substituents are methyl, chloro, fluoro, cyano, methoxy and trifluoromethoxy.

X may also be optionally substituted by C₃-cycloalkyl.

In a preferred embodiment, when X is phenyl, R¹ is preferably an optionally substituted group selected from pyrrolidinyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, tetrazolyl, oxazolyl, oxadiazolyl, piperidinyl, piperazinyl, morpholinyl, pyridyl, pyrimidinyl, thienyl, imidazolidinyl, benzimidazolyl and quinolyl. Particularly preferred groups are morpholinol, pyrrolidinyl, imidazolyl, pyridyl, oxazolyl, oxadiazolyl, pyrazolyl, piperidinyl, piperazinyl and pyrimidinyl. The optional substituents for R¹ when X is phenyl are selected independently from C₁-alkyl, C₁-alkoxy, oxy, halogen, hydroxyC₁-alkyl, -N(C₁-alkyl)₂ and -CH₂-NC₁-alkyl. Particularly preferred optional substituents are methyl and oxy.

In a preferred embodiment, when X is a bond, R¹ is selected from an optionally substituted pyrrolidinyl, isoxazolyl, furyl, thienyl, imidazolyl, pyrazolyl, tetrazolyl, oxazolyl, thiazolyl, oxadiazolyl, piperidinyl, piperazinyl, morpholinol, pyridyl, tetrahydrofuranyl, tetrahydropyridinyl and quinolyl. Particularly preferred groups are piperazinyl, piperidinyl, morpholinol, imidazolyl, thienyl and pyrrolidinyl. The optional substituents for R¹ when X is a bond are selected independently from C₁-alkyl, C₁-alkoxy, oxy, halogen, hydroxyC₁-alkyl, -N(C₁-alkyl)₂, -CH₂-NC₁-alkyl, -CO₂C₁-alkyl, phenyl optionally substituted by halogen and benzyl optionally substituted by halogen and/or cyano. Particularly preferred optional substituents are methyl and oxy.

30 In a preferred embodiment, R² is selected from hydrogen, C₁-alkyl and -CH₂-cyclopropyl, more preferably hydrogen.

35 In a preferred embodiment, R⁴ is selected from C₁-alkyl, cyclopropyl, -CH₂-cyclopropyl, pyridinyl and phenyl.

In a preferred embodiment, R⁶ is selected from hydrogen and C₁-alkyl, and phenyl optionally substituted by methyl or halogen.

In a preferred embodiment, R⁸ is selected from hydrogen and C₁-alkyl.

In a preferred embodiment, R⁷ is selected from C₁-alkyl, -NHCOCH₃, pyridinyl, pyrimidinyl and oxadiazolyl.

40 In a preferred embodiment, R⁹ is hydrogen.

In a preferred embodiment, R⁹ is C₄-alkyl.

In a preferred embodiment, W is methyl.

In a preferred embodiment, V and Y are each selected independently from hydrogen, chlorine and fluorine. In a further preferred embodiment, V is fluorine.

5 In a preferred embodiment, Z is a bond and the sum of m+n is from 0-3.

In a preferred embodiment, q is selected from 0 and 1.

In a preferred embodiment, s is selected from 0 and 1.

In a preferred embodiment, r is selected from 0 and 1. In particular, r is 0. It is to be understood that the present invention covers all combinations of particular and preferred groups described hereinabove.

Particular compounds according to the invention include those mentioned in the examples and their pharmaceutically acceptable salts and solvates. A specific example which may be mentioned is:

10 N³-Cyclopropyl-N⁴-(3-imidazol-1-ylpropyl)-6-methyl-1,1-biphenyl-3,4-dicarboxamide.

15 Further specific examples which may be mentioned include:

20 N³-Cyclopropyl-6-methyl-N⁴-(4-(4-methylpiperazin-1-yl)benzyl)-1,1-biphenyl-3,4-dicarboxamide;

30 N³-Cyclopropyl-6-methyl-N⁴-(1,3-thiazol-2-ylmethyl)-1,1-biphenyl-3,4-dicarboxamide;

35 N³-Cyclopropyl-5-fluoro-6-methyl-N⁴-(3-(morpholin-4-ylmethyl)benzyl)-1,1-biphenyl-3,4-dicarboxamide;

40 N³-Cyclopropyl-6-methyl-N⁴-(3-(morpholin-4-ylmethyl)benzyl)-1,1-biphenyl-3,4-dicarboxamide;

45 N³-Cyclopropyl-6-methyl-N⁴-(2-(4-methylpiperazin-1-yl)methyl)biphenyl-1,1-biphenyl-3,4-dicarboxamide;

50 N³-Cyclopropyl-6-methyl-N⁴-(2-(4-methylpiperazin-1-yl)methyl)biphenyl-1,1-biphenyl-3,4-dicarboxamide;

55 N³-Cyclopropyl-6-methyl-N⁴-(3-(pyrrolidin-1-ylmethyl)biphenyl)-1,1-biphenyl-3,4-dicarboxamide;

60 N³-Cyclopropyl-6-methyl-N⁴-(3-(4-methylpiperazin-1-yl)methyl)biphenyl-1,1-biphenyl-3,4-dicarboxamide; and

5

N3-Cyclopropyl-6-methyl-N4-[3-(piperidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide.

As used herein, the term "alkyl" refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms. For example, C_1 -alkyl means a straight or branched alkyl containing at least 1, and at most 6, carbon atoms. Examples of "alkyl" as used herein include, but are not limited to, methyl, ethyl, n -propyl, n -butyl, n -pentyl, isobutyl, isopropyl and t -butyl. A C_1 -alkyl group is preferred, for example methyl, ethyl or isopropyl. The said alkyl groups may be optionally substituted with one or more halogen atoms, in particular fluorine atoms, for example, trifluoromethyl.

As used herein, the term "alkoxy" refers to a straight or branched chain alkoxy group, for example, methoxy, ethoxy, propoxy, prop-2-oxy, butoxy, but-2-oxy, 2-methylprop-1-oxy, 2-methylprop-2-oxy, pentoxy, or hexoxy. A C_1 -alkoxy group is preferred, for example methoxy or ethoxy.

As used herein, the term "cycloalkyl" refers to a non-aromatic hydrocarbon ring containing the specified number of carbon atoms. For example, C_3 -cycloalkyl means a non-aromatic ring containing at least three, and at most seven, ring carbon atoms. Examples of "cycloalkyl" as used herein include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. A C_{3-8} cycloalkyl group is preferred, for example cyclopropyl.

As used herein, the terms "heteroaryl ring" and "heteroaryl" refer to an monocyclic five- to seven-membered unsaturated hydrocarbon ring containing at least one heteroatom independently selected from oxygen, nitrogen and sulfur. Preferably, the heteroaryl ring has five or six ring atoms. Examples of heteroaryl rings include, but are not limited to, furyl, thiencyl, pyrrolyl, oxazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl and triazinyl. The said ring may be optionally substituted by one or more substituents independently selected from C_1 -alkyl and oxy.

As used herein, the terms "heterocyclic ring" or "heterocyclyl" refer to a monocyclic three- to seven-membered saturated or non-aromatic, unsaturated hydrocarbon ring containing at least one heteroatom independently selected from oxygen, nitrogen and sulfur. Preferably, the heterocyclic ring has five or six ring atoms. Examples of heterocyclic groups include, but are not limited to, aziridinyl, pyrrolinyl, morpholinol, tetrahydropyranyl, tetrahydropyranyl, and thiomorpholinol. The said ring may be optionally substituted by one or more substituents independently selected from C_1 -alkyl and oxy.

As used herein, the term "fused bicyclic ring" refers to a ring system comprising two five- to seven-membered saturated or unsaturated rings, the ring system containing at least one heteroatom independently selected from oxygen, nitrogen and sulfur. Preferably, each ring has five or six ring atoms. Examples of suitable fused bicyclic

6

rings include, but are not limited to, naphthyl, indolyl, benzothienyl, quinolyl, isoquinolyl, tetrahydroisoquinolyl, benzodioxanyl, $1H$ -indyl and tetrahydronaphthyl. Each ring may be optionally substituted with one or more substituents selected from halogen, C_1 -alkyl, oxy, $-(CH_2)_pNR^{10}R^{11}$, $-CO(CH_2)_pNR^{10}R^{11}$, and imidazolyl. Particularly preferred substituents are chlorine, imidazolyl and $-CH_2N(CH_3)_2$. Particularly preferred halogens are chlorine, bromine and iodine. Preferred halogens are fluorine, chlorine and bromine. A particularly preferred halogen is fluorine.

As used herein, the term "optionally" means that the subsequently described event(s) may or may not occur, and includes both event(s) which occur and events that do not occur.

As used herein, the term "substituted" refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated.

As used herein, the term "solvate" refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I) or a salt thereof) and a solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Examples of suitable solvents include water, methanol, ethanol and acetic acid. Preferably the solvent used is a pharmaceutically acceptable solvent. Examples of suitable pharmaceutically acceptable solvents include water, ethanol and acetic acid. Most preferably the solvent used is water.

Certain compounds of formula (I) may exist in stereoisomeric forms (e.g. they may contain one or more asymmetric carbon atoms or may exhibit cis-trans isomerism). The individual stereoisomers (enantiomers and diastereomers) and mixtures of these are included within the scope of the present invention. The present invention also covers the individual isomers of the compounds represented by formula (I) as mixtures with isomers thereof in which one or more chiral centres are inverted. Likewise, it is understood that compounds of formula (I) may exist in tautomeric forms other than that shown in the formula and these are also included within the scope of the present invention.

Salts of the compounds of the present invention are also encompassed within the scope of the invention and may, for example, comprise acid addition salts resulting from reaction of an acid with a nitrogen atom present in a compound of formula (I).

Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention. Representative salts include the following salts: Acetate, Benzenesulfonate, Benzoate, Bicarbonate, Bisulfate, Bitartrate, Borate, Bromide, Calcium Edeitate, Camysylate, Carbonate, Chloride, Clavulanate, Citrate, Dihydrochloride, Edeitate, Edisylate, Estolate, Esylate, Fumarate, Glucopete, Gluconate, Glutamate, Glycolylaspartate, Hexylresorcinate, Hydramine, Hydrobromide, Hydrochloride, Hydroxynaphthoate, Iodide, Isothionate, Lactate,


7

8

Lactobionate, Laurate, Malate, Maleate, Mandelate, Mesylate, Methylbromide, Methylnitrate, Methylsulfate, Monopotassium Maleate, Muicate, Napsylate, Nitrate, N-methylglucamine, Oxalate, Pamoate (Embonate), Palmitate, Pantothenate, Phosphate/diphosphate, Polygalacturonate, Potassium, Salicylate, Sodium, Stearate, Subacetate, Succinate, Tannate, Tartrate, Teoclate, Tosylate, Triethylidide, Trimethylammonium and Valerate. Other salts which are not pharmaceutically acceptable may be useful in the preparation of compounds of this invention and these form a further aspect of the invention.

The compounds of this invention may be made by a variety of methods, including standard chemistry. Any previously defined variable will continue to have the previously defined meaning unless otherwise indicated. Illustrative general synthetic methods are set out below and then specific compounds of the invention are prepared in the working Examples.

15 For example, a general method (A) for preparing the compounds of Formula (I) comprises the reactions set out in Scheme 1 below.



Scheme 1

(I) R¹(CH₂)_mN(CH₂)_nR²H, Et₃N, THF
 (II) Bis(pinacolato)diboron, PdCl₂dppf, KOAc, DMF
 (III) (Ph₃P)₂Pd, Na₂CO₃, DME
 (IV) (COCl)₂, DMF
 (V) R⁴N⁺I⁻, pyridine

5


9

10

(vi) R^4NH_2 , PyBOP, HOBT, DIPEA, DMF

For example, a general method (B) for preparing the compounds of Formula (i) comprises the reactions set out in Scheme 2 below.


5



Scheme 2

- (i) R^4NH_2 , HATU, HOBT, DIPEA, DMF
- (ii) (4-Methoxycarbonylphenyl)boronic acid, $(Ph_3P)_4Pd$, Na_2CO_3 , DME
- (iii) $NaBH_4$, $MeOH$, H_2O
- (iv) $R^1(CH_2)_mX(CH_2)_nR^2H$, HATU, HOBT, DIPEA, THF

10



11



Scheme 3

5

- (i) $\text{CsCO}_3, (\text{Ph}_3\text{P})_2\text{Pd, DME}$
- (ii) $(\text{COCl})_2, \text{CHCl}_3$
- (iii) $\text{R}'\text{NH}_2$
- (iv) $\text{NaOH, MeOH, H}_2\text{O}$
- (v) 1-methylsulphonylbenzotriazole, $\text{Et}_3\text{N, THF, DMF}$
- (vi) $\text{R}'(\text{CH}_2)_n\text{X}(\text{CH}_2)_m\text{N R}^3\text{H, THF}$


10 Thus, according to the invention there is provided a process for preparing a compound of formula (i) which comprises:

(a) reacting a compound of formula (XIII)




15

wherein $\text{R}^1, \text{R}^2, \text{X}, \text{U}, \text{V}, \text{Y}, \text{m}, \text{n}$ and r are as defined above, with a compound of formula (XIV)



(XIV)

20 wherein $\text{R}^1, \text{R}^2, \text{X}, \text{m}$ and n are as defined above, with a compound of formula (XV)




(XV)

wherein R^4 and q are as defined above, under amide forming conditions (if desired, the acid compound (XIII) may be converted to an activated form of the acid, for example the acid chloride, by treatment with, for example, oxalyl chloride, and then the activated acid thus formed reacted with the amine compound (XV));

(b) reacting a compound of formula (XVI)

12



(XVI)


5 wherein $\text{R}^3, \text{U}, \text{W}, \text{V}, \text{Y}$ and r are as defined above, with a compound of formula (XVII)



(XVII)

10 wherein $\text{R}^1, \text{R}^2, \text{X}, \text{m}$ and n are as defined above, under amide forming conditions;

(c) reacting a compound of formula (XVII)



(XVII)

20 wherein $\text{R}^3, \text{U}, \text{W}, \text{V}, \text{Y}$ and r are as defined above, with a compound of formula (XVII) as defined above, or

20

15

(d) functional group conversion of a compound of formula (XVIII)

一

18

powders, granules, elixirs, tinctures, emulsions, solutions, syrups or suspensions prepared by conventional means with acceptable excipients.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Powders are prepared by

$$\begin{array}{c}
 \text{W} \\
 | \\
 \text{---} \text{C} \text{---} \text{C}_6\text{H}_4 \text{---} \text{C} \text{---} \text{C}(=\text{O}) \text{---} \text{N} \text{---} (\text{CH}_2)_m \text{---} \text{X} \text{---} (\text{CH}_2)_n \text{---} \text{R}^{\text{in}} \\
 | \\
 \text{(U)}_i
 \end{array}$$

118

R^2 as defined above or groups convertible to R^1 and R^2 , and R^3 and R^4 are R^1 and to give a compound of formula (I).

treating a solution of the acid, *In* for example THF, with an amine in the presence of, to

Whilst it is possible for the compounds, salts or solvates of the present invention to be administered as the new chemical, the compounds of formula (I) and their example, HOBt, HATU and DIPPEA.

15 pharmaceutically acceptable salts and solvates are conveniently administered in the form of pharmaceutical compositions.

provide a pharmaceutical composition, in another aspect of the invention, we provide a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.

The compounds of formula (I) and their pharmaceutically acceptable salts and solvates may be formulated for administration in any suitable manner. Thus, one or more of the compounds of formula (I) may be combined with one or more excipients.

example, be formulated for topical administration, or by inhalation, or more preferably, for oral, transdermal or parenteral administration. The pharmaceutical composition may be in a form such that it can effect controlled release of the compounds of formula (I) and their pharmaceutically acceptable salts and solvates. A particularly preferred method of administration, and corresponding formulation, is oral administration.

For oral administration, the pharmaceutical composition may take the form of, and be administered as, for example, tablets (including sub-lingual tablets) and capsules (each including timed release and sustained release formulations), pills,

35
40 prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil. The lubricated mixture is then compressed into tablets. The compounds of the present invention can also be combined with free flowing inert carrier and compressed into tablets directly without going through the granulating or slugging steps. A clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be

८

一

Byesters can be added to these coatings to distinguish different unit dosages.

For transdermal administration, the pharmaceutical composition may be given in the form of a transdermal patch, such as a transdermal iontophoretic patch.

5 form so that a given quantity contains a predetermined amount of the compound. Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution while dilute sirups are prepared by adding the compound to a suitable aqueous

10
solution, while extracts are prepared through the use of a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing the compound in a non-toxic vehicle. Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxyethylene sorbitol ethers, preservatives, flavor additives such as peppermint oil or saccharin, and the like can also be added.

Where appropriate, dosage unit formulations for oral administration can be microencapsulated. The formulation can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax or the like.

15 **The compounds of the present invention can also be administered in the form of**
liposomes, delivery systems such as small "inhalable" particles",
microspheres, and
microcapsules.

20 vesicles and unilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines. The compounds of the present invention can also be administered in the form of liposome emulsion delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

25 compounds or the present invention may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds of the present invention

5

30 polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide-phenol, polyhydroxyethylaspartamide-phenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a

... drug, for example, polyacetic acid, polyisopropyl caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanocrylates and cross-linked or amphiphatic block copolymers of hydrogels.

The present invention includes pharmaceutical compositions containing 0.1 to 99.5%, more particularly, 0.5 to 90% of a compound of the formula (I) in combination with a pharmaceutically acceptable carrier.

Likewise, the composition may also be administered in nasal, ophthalmic, o/c, rectal, topical, Intravenous (both bolus and infusion), intraperitoneal, intraarticular, subcutaneous or intramuscular, Inhalation or insufflation form, all using forms well known to those of ordinary skill in the pharmaceutical arts.

15 emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. For administration by injection these may take the form of a unit dose presentation or as a multidose presentation preferably with an added preservative. Alternatively for parenteral administration the active ingredient may be in powder form for reconstitution with a suitable vehicle.

The compounds of the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or

Alternatively the composition may be formulated for topical application, for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropriate conventional additives, including, for example, preservatives, solvents to

25 assist drug penetration, and emollients in ointments and creams. Such topical formulations may also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions. Such carriers may constitute from about 1% to about 98% by weight of the formulation; more usually they will constitute up to about 80% by weight of the formulation.

conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, tetrafluoroethane, heptafluoropropane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

35 The pharmaceutical compositions

40 for treatment or prophylaxis of a specific condition or conditions. Initial dosing in human is accompanied by clinical monitoring of symptoms, such symptoms for the selected condition. In general, the compositions are administered in an amount of active agent of at least about 100 $\mu\text{g}/\text{kg}$ body weight. In most cases they will be administered in one or more doses in an amount not in excess of about 20 mg/kg body weight per day. Preferably, in

17

18

most cases, dose is from about 100 $\mu\text{g}/\text{kg}$ to about 5 mg/kg body weight, daily. For administration particularly to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0.1 mg/kg to 10 mg/kg and typically around 1 mg/kg . It will be appreciated that optimum dosage will be determined by standard methods for each treatment modality and indication, taking into account the indication, its severity, route of administration, complicating conditions and the like. The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual. The effectiveness of a selected actual dose can readily be determined, for example, by measuring clinical symptoms or standard anti-inflammatory indicia after administration of the selected dose.

The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention. For conditions or disease states as are treated by the present invention, maintaining consistent daily levels in a subject over an extended period of time, e.g., in a maintenance regime, can be particularly beneficial.

In another aspect, the present invention provides a compound of formula (I) or a salt or solvate thereof, for use in therapy.

The compounds of the present invention are generally inhibitors of cytokine production which is mediated by p38 kinase. Within the meaning of the term "inhibitors of the serine/threonine kinase p38" are included those compounds that interfere with the ability of p38 to transfer a phosphate group from ATP to a protein substrate according to the assay described below.

It will be appreciated that the compounds of the invention may be selective for one or more of the isoforms of p38, for example p38 α , p38 β , p38 γ and/or p38 δ . In one embodiment, the compounds of the invention selectively inhibit the p38 α isoform. In another embodiment, the compounds of the invention selectively inhibit the p38 β isoform. In a further embodiment, the compounds of the invention selectively inhibit the p38 α and p38 β isoforms. Assays for determining the selectivity of compounds for the p38 isoforms are described in, for example, WO 99/81426, WO 00/71535 and WO 02/46158.

It is known that p38 kinase activity can be elevated (locally or throughout the body), p38 kinase can be incorrectly temporally active or expressed, p38 kinase can be expressed or active in an inappropriate location, p38 kinase can be constitutively expressed, or p38 kinase expression can be erratic; similarly, cytokine production mediated by p38 kinase activity can be occurring at inappropriate times, inappropriate locations, or it can occur at detrimentally high levels.

Accordingly, the present invention provides a method for the treatment of a condition or disease state mediated by p38 kinase activity, or mediated by cytokines produced by the activity of p38 kinase, in a subject which comprises administering to

said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof. The compound may be administered as a single or polymorphic crystalline form or forms, an amorphous form, a single enantiomer, a racemic mixture, a single stereoisomer, a mixture of stereoisomers, a single diastereoisomer or a mixture of diastereoisomers.

The present invention also provides a method of inhibiting cytokine production which is mediated by p38 kinase activity in a subject, e.g. a human, which comprises administering to said subject in need of cytokine production inhibition a therapeutic, or cytokine-inhibiting, amount of a compound of the present invention. The compound may be administered as a single or polymorphic crystalline form or forms, an amorphous form, a single enantiomer, a racemic mixture, a single stereoisomer, a mixture of stereoisomers, a single diastereoisomer or a mixture of diastereoisomers.

The present invention treats these conditions by providing a therapeutically effective amount of a compound of this invention. By "therapeutically effective amount" is meant a symptom-alleviating or symptom-reducing amount, a cytokine-reducing amount, a cytokine-inhibiting amount, a kinase-regulating amount and/or a kinase-inhibiting amount of a compound. Such amounts can be readily determined by standard methods, such as by measuring cytokine levels or observing alleviation of clinical symptoms. For example, the clinician can monitor accepted measurement scores for anti-inflammatory treatments.

The compounds of the present invention can be administered to any subject in need of inhibition or regulation of p38 kinase or in need of inhibition or regulation of p38 mediated cytokine production. In particular, the compounds may be administered to mammals. Such mammals can include, for example, horses, cows, sheep, pigs, mice, dogs, cats, primates such as chimpanzees, gorillas, rhesus monkeys, and, most preferably, humans.

Thus, the present invention provides methods of treating or reducing symptoms in a human or animal subject suffering from, for example, rheumatoid arthritis, osteoarthritis, asthma, psoriasis, eczema, allergic rhinitis, allergic conjunctivitis, adult respiratory distress syndrome, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, silicosis, endoxemias, toxic shock syndrome, inflammatory bowel disease, tuberculosis, atherosclerosis, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, epilepsy, multiple sclerosis, aneurism, stroke, irritable bowel syndrome, muscle degeneration, bone resorption diseases, osteoporosis, diabetes, reperfusion injury, graft vs. host reaction, allograft rejections, sepsis, systemic cachexia, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), malaria, leprosy, infectious arthritis, leishmaniasis, Lyme disease, glomerulonephritis, gout, psoriatic arthritis, Reiter's syndrome, traumatic arthritis, rubella arthritis, Crohn's disease, ulcerative colitis, acute synovitis, gouty arthritis, spondylitis,

5
10
15
20
25
30
35
40

most cases, dose is from about 100 $\mu\text{g}/\text{kg}$ to about 5 mg/kg body weight, daily. For administration particularly to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0.1 mg/kg to 10 mg/kg and typically around 1 mg/kg . It will be appreciated that optimum dosage will be determined by standard methods for each treatment modality and indication, taking into account the indication, its severity, route of administration, complicating conditions and the like. The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual. The effectiveness of a selected actual dose can readily be determined, for example, by measuring clinical symptoms or standard anti-inflammatory indicia after administration of the selected dose.

The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention. For conditions or disease states as are treated by the present invention, maintaining consistent daily levels in a subject over an extended period of time, e.g., in a maintenance regime, can be particularly beneficial.

In another aspect, the present invention provides a compound of formula (I) or a salt or solvate thereof, for use in therapy.

The compounds of the present invention are generally inhibitors of cytokine production which is mediated by p38 kinase. Within the meaning of the term "inhibitors of the serine/threonine kinase p38" are included those compounds that interfere with the ability of p38 to transfer a phosphate group from ATP to a protein substrate according to the assay described below.

It will be appreciated that the compounds of the invention may be selective for one or more of the isoforms of p38, for example p38 α , p38 β , p38 γ and/or p38 δ . In one embodiment, the compounds of the invention selectively inhibit the p38 α isoform. In another embodiment, the compounds of the invention selectively inhibit the p38 β isoform. In a further embodiment, the compounds of the invention selectively inhibit the p38 α and p38 β isoforms. Assays for determining the selectivity of compounds for the p38 isoforms are described in, for example, WO 99/81426, WO 00/71535 and WO 02/46158.

It is known that p38 kinase activity can be elevated (locally or throughout the body), p38 kinase can be incorrectly temporally active or expressed, p38 kinase can be expressed or active in an inappropriate location, p38 kinase can be constitutively expressed, or p38 kinase expression can be erratic; similarly, cytokine production mediated by p38 kinase activity can be occurring at inappropriate times, inappropriate locations, or it can occur at detrimentally high levels.

Accordingly, the present invention provides a method for the treatment of a condition or disease state mediated by p38 kinase activity, or mediated by cytokines produced by the activity of p38 kinase, in a subject which comprises administering to

19

20

and non articular inflammatory conditions, for example, herniated/ruptured/prolapsed intervertebral disk syndrome, bursitis, tendinitis, tenosynovitis, fibromyalgic syndrome and other inflammatory conditions associated with ligamentous sprain and regional musculoskeletal strain, pain, for example that associated with inflammation and/or trauma, osteoporosis, restenosis, thrombosis, angiogenesis, cancer including breast cancer, colon cancer, lung cancer or prostatic cancer, which comprises administering to said subject a therapeutically effective amount of a compound of formula(I) or a pharmaceutically acceptable salt or solvate thereof.

A further aspect of the invention provides a method of treatment of a human or animal subject suffering from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis, Crohn's disease, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, epilepsy and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer, which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

A further aspect of the invention provides a method of treatment of a human or animal subject suffering from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic

cachexia, glomerulonephritis, Crohn's disease and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer, which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

A further aspect of the invention provides a method of treatment of a human or animal subject suffering from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic

cachexia, glomerulonephritis, Crohn's disease and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer, which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

A further aspect of the invention provides a method of treatment of a human or animal subject suffering from rheumatoid arthritis, neurodegenerative disease, Alzheimer's disease, Parkinson's disease and epilepsy which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

A further aspect of the invention provides a method of treatment of a human or animal subject suffering from any type of pain including chronic pain, rapid onset of pain associated with osteoarthritis and rheumatoid arthritis, post operative inflammatory pain, neuropathic pain, diabetic neuropathy, trigeminal neuralgia, post-hepatic neuralgia, inflammatory neuropathies and migraine pain which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof.

A further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of a condition or disease state selected from rheumatoid arthritis, osteoarthritis, asthma, psoriasis, eczema, allergic rhinitis, allergic conjunctivitis, trauma, osteoporosis, restenosis, thrombosis, angiogenesis, cancer including breast cancer, colon cancer, lung cancer or prostatic cancer, which comprises administering to said subject a therapeutically effective amount of a compound of formula(I) or a pharmaceutically acceptable salt or solvate thereof.

A further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by p38 kinase activity.

A further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of a condition or disease state selected from rheumatoid

5

10

15

20

25

30

35

40

40

5

10

15

20

25

30

35

40

40

A further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of a condition or disease state selected from rheumatoid arthritis, osteoarthritis, asthma, psoriasis, eczema, allergic rhinitis, allergic conjunctivitis, adult respiratory distress syndrome, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, silicosis, endotoxemia, toxic shock syndrome, inflammatory bowel disease, tuberculosis, atherosclerosis, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, epilepsy, multiple sclerosis, aneurism, stroke, irritable bowel syndrome, muscle degeneration, bone resorption diseases, osteoporosis, diabetes, reperfusion injury, graft vs. host reaction, allograft rejections, sepsis, systemic cachexia, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), malnutrition, leprosy, infectious arthritis, leishmaniasis, Lyme disease, glomerulonephritis, gout, psoriatic arthritis, Reiters syndrome, traumatic arthritis, rubella arthritis, Crohn's disease, ulcerative colitis, acute synovitis, gouty arthritis, spondylitis, and non articular inflammatory conditions, for example, herniated/ruptured/prolapsed intervertebral disk syndrome, bursitis, tendinitis, tenosynovitis, fibromyalgic syndrome and other inflammatory conditions associated with ligamentous sprain and regional musculoskeletal strain, pain, for example that associated with inflammation and/or trauma, osteoporosis, restenosis, thrombosis, angiogenesis, and cancer including breast cancer, colon cancer, lung cancer or prostatic cancer.

A further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of a condition or disease state selected from rheumatoid arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis, Crohn's disease, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, epilepsy, and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer.

A further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of a condition or disease state selected from rheumatoid

arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis, Crohn's disease and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer.

A further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of a condition or disease state selected from rheumatoid

arthritis, asthma, psoriasis, chronic pulmonary inflammation, chronic obstructive pulmonary disease, chronic heart failure, systemic cachexia, glomerulonephritis, Crohn's disease and cancer including breast cancer, colon cancer, lung cancer and prostatic cancer.

21

22

arthritis, neurodegenerative disease, Alzheimer's disease, Parkinson's disease and epilepsy.

A further aspect of the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of any type of pain including chronic pain, rapid onset of analgesis, neuromuscular pain, headache, cancer pain, acute and chronic inflammatory pain, neuropathic pain, diabetic neuropathy, trigeminal neuralgia, post-hepatic neuralgia, inflammatory neuropathies and migraine pain.

The compounds of formula (I) and their salts, solvates and physiologically functional salts and solvates may be employed alone or in combination with other therapeutic agents for the treatment of the above-mentioned conditions. In particular, in rheumatoid arthritis therapy, combination with other chemotherapeutic or antibody agents is envisaged. Combination therapies according to the present invention thus comprise the administration of at least one compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof and at least one other pharmaceutically active agent. The compound(s) of formula (I) or pharmaceutically acceptable salt(s) or solvate(s) thereof and the other pharmaceutically active agent(s) may be administered together or separately and, when administered separately, this may occur separately or sequentially in any order. The amounts of the compound(s) of formula (I) or pharmaceutically acceptable salt(s) or solvate(s) thereof and the other pharmaceutically active agent(s) and the relative timings of administration will be selected in order to achieve the desired combined therapeutic effect. Examples of other pharmaceutically active agents which may be employed in combination with compounds of formula (I) and their salts and solvates for rheumatoid arthritis therapy include: immunosuppressants such as antitumour necrosis factor agents such as etanercept, infliximab, diacerein; tyrosine kinase inhibitors such as leflunomide; kallikrein antagonists such as subrune; interferon 11 agonists such as oprelvekin; interferon beta 1 agonists; hyaluronic acid agonists such as NRD-101 (Aventis); Interleukin 1 receptor antagonists such as anakinra; CDB antagonists such as amipirose hydrochloride; beta amyloid precursor protein antagonists such as reumacon; matrix metalloprotease inhibitors such as ciprosat and other disease modifying anti-rheumatic drugs (DMARDs) such as methotrexate, sulphasalazine, cyclosporin A, hydroxychloroquine, auranofin, aurothioglucose, gold sodium thiomalate and penicillamine.

Examples

The following examples are illustrative embodiments of the invention, not limiting the scope of the invention in any way. Reagents are commercially available or are prepared according to procedures in the literature.

LCMS was conducted on a column (3.3cm x 4.6mm ID, 3um ABZ+PLUS), at a Flow Rate of 3ml/min, Injection Volume of 5μl, at room temperature and UV Detection Range at 215 to 330nm.

5

5

General Method A:

Benzolic acid (0.17mmol), HATU (0.2mmol), HOBT (0.17mmol), DIPEA (0.51mmol), and amine (0.2mmol) were mixed in DMF (2ml) and the reaction stirred at room temperature for 24h. Further portions of amine (0.05mmol) and HATU (0.052mmol) were added and the mixture heated for 18h at 60°C. The solvent was evaporated under vacuum and the residue partitioned between DCM (5ml) and aqueous sodium carbonate (1M, 5ml). The organic phase was reduced to dryness under vacuum and the amide purified as specified in the example.

10

10

Example 1: N³-Cyclopropyl-6-methyl-N⁴-(4-methylpiperazin-1-yl)-1,1-biphenyl-3,4-dicarboxamide

a) N³-Cyclopropyl-6-methyl-N⁴-(4-methylpiperazin-1-yl)-1,1-biphenyl-3,4-dicarboxamide was synthesised from 3'-(cyclopropylamino)carbonyl-6'-methyl-1,1'-biphenyl-4'-yl)carboxylic acid and 1-methylpiperazine using method A. Purified by chromatography on an SPE (silica, 5g) eluting with a DCM/Methanol/ammonia gradient (500:8:1 to 40:8:1). NMR: δH [¹H] - DMSO 8.42,(1H, d), 7.85,(1H, dd), 7.69,(1H, d), 7.46,(2H, d), 7.43,(2H, d), 7.38,(1H, d), 3.62,(2H, b), 2.84,(1H, m), 2.32,(6H, b), 2.27,(3H, s), 2.20,(3H, s), 0.67,(2H, m), 0.55,(2H, m). LCMS: retention time 2.10min, MH⁺378.

15

Example 2: N³-Cyclopropylamino-6-methyl-1,1-biphenyl-4'-yl)carboxylic acid

b) 3'-(Cyclopropylamino)carbonyl-6'-methyl-1,1-biphenyl-4'-yl)carboxylic acid (2.7g, 8.7mmol) and lithium hydroxide monohydrate (0.77g, 18.3mmol) were mixed in THF (20ml) and water (10ml) and heated at 80°C for 2h. The THF was evaporated under vacuum and hydrochloric acid (2N) added to the aqueous with vigorous stirring. The solid produced was filtered off, dissolved in methanol and absorbed onto silica. Purified by flash column chromatography eluting with DCM/Methanol/ammonia (20:8:1). The product fractions were concentrated under vacuum to give 3'-(cyclopropylamino)carbonyl-6'-methyl-1,1-biphenyl-4'-yl)carboxylic acid (2.0g, 78%). LCMS: retention time 2.94min, MH⁺256.

20

Example 3: Methyl 3'-(cyclopropylamino)carbonyl-6'-methyl-1,1-biphenyl-4'-yl)carboxylate

c) Methyl 3'-(cyclopropylamino)carbonyl-6'-methyl-1,1-biphenyl-4'-yl)carboxylate (4-
methoxycarbonylphenyl)boronic acid (3.4g, 18.7mmol), aqueous sodium carbonate (1M, 50ml) and tetrakis(triphenylphosphine)palladium (1.8g, 0.156mmol) in DME (100ml) were heated at 95°C for 18h. The reaction mixture was absorbed onto silica and purified by flash column chromatography eluting with DCM/Methanol/ammonia (50:8:1).

25

Example 4: Methyl 3'-(cyclopropylamino)carbonyl-6'-methyl-1,1-biphenyl-4'-yl)carboxylate

d) Methyl 3'-(cyclopropylamino)carbonyl-6'-methyl-1,1-biphenyl-4'-yl)carboxylate (4-
methoxycarbonylphenyl)boronic acid (3.4g, 18.7mmol), aqueous sodium carbonate (1M, 50ml) and tetrakis(triphenylphosphine)palladium (1.8g, 0.156mmol) in DME (100ml) were heated at 95°C for 18h. The reaction mixture was absorbed onto silica and purified by flash column chromatography eluting with DCM/Methanol/ammonia (50:8:1).

30

Example 5: Methyl 3'-(cyclopropylamino)carbonyl-6'-methyl-1,1-biphenyl-4'-yl)carboxylate

e) Methyl 3'-(cyclopropylamino)carbonyl-6'-methyl-1,1-biphenyl-4'-yl)carboxylate (4-
methoxycarbonylphenyl)boronic acid (3.4g, 18.7mmol), aqueous sodium carbonate (1M, 50ml) and tetrakis(triphenylphosphine)palladium (1.8g, 0.156mmol) in DME (100ml) were heated at 95°C for 18h. The reaction mixture was absorbed onto silica and purified by flash column chromatography eluting with DCM/Methanol/ammonia (50:8:1).

35

Example 6: Methyl 3'-(cyclopropylamino)carbonyl-6'-methyl-1,1-biphenyl-4'-yl)carboxylate

The product fractions were reduced to dryness under vacuum to give methyl 3'-(cyclopropylamino)carboxylic acid (2.76g, 57%).

LCMS: retention time 3.21min, MH^+ 310.

d) ***N*³-Cyclopropyl-3-iodo-4-methylbenzamide**

3-*Iodo*-4-methylbenzoic acid (5g, 18.1mmol) and HATU (8.71g, 22.9mmol) in DMF (25ml) were stirred at room temperature for 10minutes. HOBT (2.58g, 19.1mmol), cyclopropylamine (1.37g, 22.9mmol) and DIPEA (2.5ml, 57.3mmol) were added and stirring continued for 18h. The DMF was evaporated under vacuum and the residue

partitioned between DCM (100ml) and aqueous sodium carbonate (1M, 75ml). The aqueous layer was extracted with DCM (50ml) and the combined organic phases washed with brine (75ml) and dried (magnesium sulphate). The solution was absorbed onto silica and purified by chromatography on silica eluting with ethyl acetate/cyclohexane (1:3). The product fractions were reduced to dryness under vacuum to give *N*-cyclopropyl-3-*iodo*-4-methylbenzamide (4.7g, 82%). LCMS: retention time 3.09min, MH^+ 302.

Example 2: *N*³-Cyclopropyl-*N'*-[3-imidazol-1-ylpropyl]-6-methyl-1,1-biphenyl-3,4-dicarboxamide

10 ***N*³-Cyclopropyl-*N'*-(3-imidazol-1-ylpropyl)-6-methyl-1,1-biphenyl-3,4'-dicarboxamide**

20 was synthesised from 3'-(cyclopropylamino)carboxylic acid and 1-(3-aminopropyl)imidazole using method A. Purified by chromatography on silica, eluting with a DCM/Methanol/ammonia gradient (200:8:1 to 75:8:1). NMR: δ H [¹H₆] – DMSO 8.58,(1H, t), 8.43,(1H, d), 7.93,(2H, d), 7.75,(1H, dd), 7.68,(1H, d), 7.68,(1H, s), 7.47,(2H, d), 7.38,(1H, d), 7.21,(1H, s), 6.89,(1H, s), 4.03,(2H, q), 3.26,(2H, q), 2.83,(1H, m), 2.26,(3H, s), 1.97,(2H, m), 0.67,(2H, m), 0.55,(2H, m). LCMS: retention time 2.20min, MH^+ 403.

Example 3: *N*³-Cyclopropyl-6-methyl-*N'*-[3-morpholin-4-ylpropyl]-1,1-biphenyl-3,4'-dicarboxamide

30 ***N*³-Cyclopropyl-6-methyl-*N'*-(3-morpholin-4-ylpropyl)-1,1-biphenyl-3,4'-dicarboxamide**

35 was synthesised from 3'-(cyclopropylamino)carboxylic acid and 4-(3-aminopropyl)morpholine using method A. Purified by chromatography on silica, eluting with a DCM/methanol/ammonia gradient (200:8:1 to 75:8:1). NMR: δ H [¹H₆] – DMSO 8.55,(1H, t), 8.42,(1H, d), 7.91,(2H, d), 7.74,(1H, dd), 7.68,(1H, d), 7.46,(2H, d), 7.38,(1H, d), 3.56,(4H, t), 3.30,(2H, m), 2.83,(1H, m), 2.26,(3H, s), 1.69,(2H, m), 0.67,(2H, m), 0.54,(2H, m). LCMS: retention time 2.28min, MH^+ 422.

Example 4: *N*³-Cyclopropyl-6-methyl-*N'*-[3-(4-methylpiperazin-1-yl)propyl]-1,1-biphenyl-3,4'-dicarboxamide

35 ***N*³-Cyclopropyl-6-methyl-*N'*-(3-(4-methylpiperazin-1-yl)propyl)-1,1-biphenyl-3,4'-dicarboxamide**

35 was synthesised from 3'-(cyclopropylamino)carboxylic acid (2.76g, 57%).

LCMS: retention time 3.21min, MH^+ 310.

biphenyl-4-yl)carboxylic acid and 1-(3-aminopropyl)-4-methylpiperazine using method A. Purified by chromatography on silica, eluting with a DCM/Methanol/ammonia gradient (100:8:1 to 40:8:1). NMR: δ H [¹H₆] – DMSO 8.56,(1H, t), 8.42,(1H, d), 7.91,(2H, d), 7.74,(1H, dd), 7.68,(1H, d), 7.45,(2H, d), 7.38,(1H, d), 3.30,(2H, m), 2.83,(1H, m), 2.48-2.17,(3H, m), 2.14,(3H, s), 1.68,(2H, m), 0.67,(2H, m), 0.54,(2H, m). LCMS: retention time 2.2min, MH^+ 435.

Example 5: *N*⁴'-(3-imidazol-1-ylpropyl)-6-methyl-*N*³-propyl-1,1-biphenyl-3,4'-dicarboxamide

a) **5'-(1H-1,2,3-Benzotriazol-1-yl)carboxyl-2'-methyl-*N*-propyl-1,1-biphenyl-3-carboxamide**

10 (25mg, 0.052mmol) in THF (1ml) was mixed with 1-(3-aminopropyl)imidazole (7.2 μ l) in THF (0.6ml) and the reaction stirred at room temperature for 4h. The reaction was loaded onto an SPE (aminopropyl, 1g) and eluted with chloroform, ethyl acetate and methanol. The methanol fraction was applied to an SPE (SCX, 0.5g), washed with methanol and eluted with methanol/ammonia. The solvent was evaporated from the methanol/ammonia fractions to give *N*⁴'-(3-imidazol-1-ylpropyl)-6-methyl-*N*-propyl-1,1-biphenyl-3,4'-dicarboxamide.

b) **4'-(1H-1,2,3-Benzotriazol-1-yl)carboxyl-6-methyl-*N*-propyl-1,1-biphenyl-3-carboxamide**

20 6-Methyl-3'-(propylamino)carboxylic acid (121mg, 0.41mmol), triethylamine (100 μ l) and 1-(methylsulphonyl)-1H-benzotriazole (118mg, 0.6mmol) were mixed in THF (3ml) and DMF (0.5ml) and heated at reflux for 3h. The reaction was concentrated under vacuum and partitioned between chloroform (5ml) and water (5ml). The aqueous was washed with chloroform (3ml) and the combined organics reduced to dryness under vacuum. The residue was chromatographed on an SPE (silica, 5g) eluting with chloroform, ether and ethylacetate, which after evaporation of the solvent under vacuum gave 4'-(1H-1,2,3-benzotriazol-1-yl)carboxyl-6-methyl-*N*-propyl-1,1-biphenyl-3-carboxamide (150mg).

c) **6-Methyl-6'-methyl-3'-(propylamino)carboxylic acid**

30 Methyl 6'-methyl-3'-(propylamino)carboxylic acid (216mg, 0.7mmol) in methanol (4ml) was mixed with aqueous sodium hydroxide (2N, 1ml) and stirred at room temperature for 2h. The methanol was evaporated, the reaction diluted with water (4ml) and extracted with chloroform (2x 5ml). The aqueous was acidified with hydrochloric acid (2N, 2ml) and extracted with chloroform (2x 6ml). Both sets of organic extracts were combined in methanol (4ml) and stirred with aqueous sodium hydroxide (2N, 2ml) for 3h. The methanol was evaporated, the reaction diluted with water (4ml) and washed with chloroform (2x 5ml). The aqueous was acidified with hydrochloric acid (2N, 2ml) and extracted with chloroform (2x 6ml). The solvent was

25

26

evaporated from the organic extracts to give 6'-methyl-3'-(propylamino)carboxyl-1,1'-biphenyl-4-carboxylic acid (121mg). NMR: δ H CDCl₃ 8.13(2H, d), 7.59(1H, dd), 7.62(1H, d), 7.41(2H, d), 7.35(1H, d), 3.42(2H, t), 2.30(3H, s), 1.64(2H, m), 0.98(3H, t).

5 5 Methyl 6'-methyl-3'-(propylamino)carboxyl-1,1'-biphenyl-4-carboxylate (121mg) was added to a solution of 3'-(cyclopropylcarboxyl)amino-6'-methyl-biphen-4-ylcarboxylic acid (50mg, 0.17mmol) in DMF (2ml). After 5 minutes HOBT (23mg, 0.17mmol), the chosen amine (0.17mmol) and DIPEA (0.087ml, 0.51mmol) were added and the reaction mixture stirred at room temperature under nitrogen for 18 hours. The DMF was removed *in vacuo* and the residue partitioned between DCM (5ml) and aqueous sodium carbonate (1M, 5ml). The layers were separated and the organic layer purified by SPE cartridge (Si, 5g) eluting in turn with DCM, chloroform, ether, ethyl acetate, acetonitrile, acetone, ethanol and DCM/Methanol/ammonia (40:8:1, 20:8:1, 10:8:1) to give the desired products.

10 10 Methyl 6'-methyl-3'-(propylamino)carboxyl-1,1'-biphenyl-4-carboxylate (216mg). LC/MS: retention time 3.26min, MH⁺ 312.

e) 4'-(Methoxycarbonyl)-6-methyl-1,1'-biphenyl-3-carboxylic acid

15 15 3-iodo-4-methoxybenzoic acid (8.7g, 33.3mmol), (4-methoxycarbonylphenyl)boronic acid (6.0g, 33.3mmol), caesium carbonate (10.8g, 33.3mmol) and tetrakis(triphenylphosphine)palladium (1.92g, 1.67mmol) in DME (120ml) were heated at 90°C for 8h. The cooled reaction mixture was filtered and the residue washed with DME. The combined filtrate and washings were absorbed onto silica and chromatographed on a silica flash column eluting with DCM/ethanol/ ammonia (40:8:1 then 30:8:1). The product fractions were reduced to dryness under vacuum to give 4'-(methoxycarbonyl)-6-methyl-1,1'-biphenyl-3-carboxylic acid (2.28g, 25%). LCMS: retention time 3.22min, [M-H]⁻ 269.

20 20 1-(Methysulphonyl)-1-H-benzotriazolite (3.3ml, 0.12mol) in toluene (30ml) was added dropwise to a solution of benzotriazole (11.9g, 0.1mol) and pyridine (12ml, 0.16mol) in toluene (120ml). The reaction was stirred at room temperature for 20h, diluted with ethyl acetate (150ml), washed with water (2x 100ml), brine (150ml) and dried (magnesium sulphate). The solvent was evaporated under vacuum to give 1-(methylsulphonyl)-1H-benzotriazole (19g). NMR: δ H CDCl₃ 8.17(1H, m), 8.02(1H, m), 7.69(1H, m), 7.55(1H, m), 3.52(3H, s).

30 30 Example 6: N³-Cyclopropyl-6-methyl-N⁴-[4-(4-methylbiphenyl-1-yl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 7: N³-Cyclopropyl-6-methyl-N⁴-[3-(4-methylbiphenyl-1-yl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 8: N³-Cyclopropyl-6-methyl-N⁴-[3-(4-methylbiphenyl-1-yl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

35 35 General Method B:

30 30 3-Bromo-N-(cyclopropyl-5-fluoro-4-methylbenzyl)benzoyl-1,1'-biphenyl-3,4'-dicarboxamide (Intermediate 2, 120mg, 0.45mmol), 4-(4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid (111mg, 0.45mmol) and tetrakis(triphenylphosphine)palladium (5mg, 0.045mmol) were dissolved in DME (3ml) and aqueous sodium carbonate (1M, 450 μ l) was added. The

Compound	Amine	MH ⁺	Retention time (minutes)
Example 6	1-methyl-4-(4-aminomethyl-phenyl)piperazine	483	2.37
Example 7	2-aminomethylbenzazole	392	2.88
Example 8	1-(3-aminobenzyl)-4-methyl-piperazine	483	2.50

Example 9: N³-Cyclopropyl-5-fluoro-6-methyl-N⁴-[3-(morpholin-4-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

15 15 {3'-(Cyclopropylamino)carboxyl-5'-fluoro-6-methyl-1,1'-biphen-4-yl}carboxylic acid (Intermediate 1, 31mg, 0.10mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (21mg, 0.11mmol), HOBT (15mg, 0.11mmol) and 4-(3-aminomethylbenzyl)morpholine (Intermediate 3, 0.11mmol) were dissolved in DMF (4ml). DIPEA (19 μ l, 0.11mmol) was added to the solution which was then stirred for 5 hours at 40°C. Ethyl acetate (25ml) and water (25ml) were added. The ethyl acetate layer was separated and washed sequentially with saturated sodium hydrogen carbonate and hydrochloric acid (0.5M). The solvent was removed *in vacuo* and the residue was purified by mass-directed HPLC to give N³-cyclopropyl-5-fluoro-6-methyl-N⁴-[3-(morpholin-4-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide.

20 20 LCMS: MH⁺ 502, 3.02minutes.

25 25 (a) {3'-(Cyclopropylamino)carboxyl-5-fluoro-6-methyl-1,1'-biphen-4-yl}carboxylic acid (Intermediate 1)

mixture was refluxed at 80°C for 16 hours. Solvent was removed *in vacuo* and the residue was purified by silica biolage chromatography, eluting with 2:1 ethyl acetate: cyclohexane followed by 9:1 ethyl acetate:methanol. To give {3-[cyclopropylamino]carbonyl-5-fluoro-5-methyl-1,1'-biphen-4-yl]carboxylic acid (1129mg, 91%).

LCMS: MH⁺ 314, retention time 3.06 min.

(b) 3-Bromo-N-cyclopropyl-5-fluoro-4-methylbenzamide (Intermediate 2)

3-Fluoro-4-methylbenzoic acid (462mg, 3.0mmol) was added to a stirred mixture of bromine (2.31ml, 45mmol) and iron powder (252mg, 4.5mmol) under nitrogen. The reaction was stirred at 20°C for 4 hours and then left to stand for 16 hours. Sodium thiosulphate solution (200ml) was added and the product was extracted into ethyl acetate (3 x 150ml). Ethyl acetate extracts were combined and evaporated *in vacuo*. The crude product (mixture of isomers) was dissolved in DMF (7ml). Cyclopropylamine (206µl, 3.0mmol), HOBT (405mg, 3.0mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (575mg, 3.0mmol) and DIPEA (525µl, 3.0mmol) were added to the stirred solution. The reaction was stirred for 5 hours at 20°C. Solvent was removed *in vacuo* and the residue was partitioned between ethyl acetate and water. Combined ethyl acetate extracts were washed sequentially with aqueous sodium hydrogen carbonate and hydrochloric acid (0.5M), then dried (magnesium sulphate). The ethyl acetate was evaporated *in vacuo* and the residue was purified by silica biolage chromatography eluting with cyclohexane/ethyl acetate (6:1) to give 3-bromo-N-cyclopropyl-5-fluoro-4-methylbenzamide (359mg, 44%).

NMR: 5H – CDCl₃, 7.08,(1H, s), 7.39,(1H, d), 8.19,(1H, bs), 2.88,(1H, m), 2.36,(3H, d), 0.88,(2H, m), 0.63,(2H, m). LCMS: MH⁺ 272/274, retention time 3.12 min.

(c) 4-(3-Aminomethylbenzyl)morpholine (Intermediate 3)

3-Fluoro-4-methylbenzoic acid (462mg, 3.0mmol) was added to a stirred mixture of bromine (2.31ml, 45mmol) and iron powder (252mg, 4.5mmol) under nitrogen. The reaction was stirred at 20°C for 4 hours and then left to stand for 16 hours. Sodium thiosulphate solution (200ml) was added and the product was extracted into ethyl acetate (3 x 150ml). Ethyl acetate extracts were combined and evaporated *in vacuo*. The crude product (mixture of isomers) was dissolved in DMF (7ml). Cyclopropylamine (206µl, 3.0mmol), HOBT (405mg, 3.0mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (575mg, 3.0mmol) and DIPEA (525µl, 3.0mmol) were added to the stirred solution. The reaction was stirred for 5 hours at 20°C. Solvent was removed *in vacuo* and the residue was partitioned between ethyl acetate and water. Combined ethyl acetate extracts were washed sequentially with aqueous sodium hydrogen carbonate and hydrochloric acid (0.5M), then dried (magnesium sulphate). The ethyl acetate was evaporated *in vacuo* and the residue was purified by silica biolage chromatography eluting with cyclohexane/ethyl acetate (6:1) to give 3-bromo-N-cyclopropyl-5-fluoro-4-methylbenzamide (359mg, 44%).

NMR: 5H – CDCl₃, 7.08,(1H, s), 7.39,(1H, d), 8.19,(1H, bs), 2.88,(1H, m), 2.36,(3H, d), 0.88,(2H, m), 0.63,(2H, m). LCMS: MH⁺ 272/274, retention time 3.12 min.

(d) N-tert-Butyloxycarbonyl-3-(4-morpholinylmethylbenzyl)-carbamic acid tert-butyl ester (Intermediate 4)

Morpholine (2.3ml) was added to a solution of (3-chloromethylbenzyl)-carbamic acid tert-butyl ester (Intermediate 5, 1.7g) in THF (20ml) and the mixture heated at reflux under nitrogen for 6 hours. Concentration of the reaction under vacuum gave N-tert-butyloxycarbonyl-3-(4-morpholinylmethylbenzyl)amine (1.94g).

NMR: 5H – CDCl₃, 7.41-7.16,(4H, m), 4.97,(1H, b), 4.42,(2H, b), 3.72,(4H, m), 3.50,(2H, s), 2.45,(4H, m), 1.5,(9H, s). MS: MH⁺ 307.

(e) (3-Chloromethylbenzyl)-carbamic acid tert-butyl ester (Intermediate 5)

Triethylamine (21.27ml, 152.6mmol) was added to a suspension of 3-chloromethylbenzylamine hydrochloride (Intermediate 6, 167.92mmol) in dry THF (180ml). A solution of di-tert-butyl dicarbonate (14.75g, 67.58mmol) in dry THF (50ml) was added dropwise at 0°C. Once the addition was complete, the reaction mixture was stirred at room temperature for 18 hours. The mixture was filtered and the filtrate concentrated *in vacuo*. The residue was dissolved in ethyl acetate (250ml) and washed with water (150ml). The aqueous layer was extracted with ethyl acetate (50ml). The combined organic extracts were washed with cold hydrochloric acid (1N, 80ml), aqueous sodium hydrogen carbonate solution (100ml), dried (magnesium sulphate), filtered and concentrated *in vacuo* to give (3-Chloromethylbenzyl)-carbamic acid tert-butyl ester (123.46.9mmol).

MS: MNH⁺ 273.

(f) 3-Chloromethylbenzylamine hydrochloride (Intermediate 6)

Hexamethylene diamine (27.13g, 0.194mol) was added to a solution of dichloro-m-xylene (34g, 0.194mol) in chloroform (230ml) and the mixture heated at reflux for 30 minutes. The cooled reaction was filtered and the filtrate reduced to dryness under vacuum. The residue was dissolved in ethanol (340ml), treated with concentrated hydrochloric acid (32ml) and heated at reflux for 3 hours. The reaction was reduced to 4ml under vacuum, diluted with ether (250ml) and filtered to give 3-chloromethylbenzylamine hydrochloride (10.57g).

MS: MH⁺ 156.

Example 10: N³-Cyclopropyl-6-methyl-N⁴-(3-(morpholin-4-ylmethylbenzyl)-1,1'-biphenyl-3,4'-dicarboxamide

29

30

Example 11: *N*³-Cyclopropyl-6-methyl-*N*⁴-[2-(4-methylpiperazin-1-yl)methyl]biphenyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 12: *tert*-Butyl 4-[(5-[(cyclopropylamino)carbonyl]-2'-methyl-1,1'-biphenyl-4-yl)carboxylate

Example 13: *N*³-Cyclopropyl-6-methyl-*N*⁴-[2-(4-methylpiperazin-1-yl)phenyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 14: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(4-methylpiperazin-1-yl)phenyl]-1,1'-biphenyl-3,4'-dicarboxamide

10 General Method C:

HATU (65mg, 0.17mmol) was added to a solution of {3'-(cyclopropylcarbonyl)amino}-6-methyl-biphenyl-4-yl]carboxylic acid (50mg, 0.17mmol) in DMF (2ml). After 5 minutes HOBt (23mg, 0.17mmol), the amine (0.17mmol) and DIPEA (0.087ml, 0.51mmol) were added and the reaction mixture stirred at room temperature under nitrogen for 18 hours. The reaction was partitioned between ethyl acetate (50ml) and hydrochloric acid (1M, 50ml). The organic phase was washed with aqueous sodium carbonate (1M, 50ml) and brine (25ml), dried (magnesium sulphate), and the solvent removed *in vacuo*. The crude material was purified by Biotage cartridge (S1, 8g) eluting with a toluene:ethanol gradient (95:5 to 70:30) to yield the desired products.

Compound	Amine	MH ⁺	Retention time
Example 10	4-(3-aminomethylbenzyl)morpholine	484	(minutes)
Example 11	1-(2-aminobenzyl)-4-methylpiperazine	483	2.43
Example 12	4-(aminomethyl)piperidine-1-carboxylic acid (<i>tert</i> -butyl ester)	492	3.31
Example 13	1-(2-aminophenyl)-4-methylpiperazine	469	2.44
Example 14	1-(3-aminophenyl)-4-methylpiperazine	469	2.41

Example 17: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(morpholin-4-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 18: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(4-methylpiperazin-1-yl)methyl]biphenyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 19: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(pyridin-4-ylmethyl)-1,1'-biphenyl-3,4'-dicarboxamide

Example 20: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(piperidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 21: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(pyrrolidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 22: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(1H-imidazol-1-ylmethyl)benzyl]-6-methyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 23: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(piperidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 24: *N*³-Cyclopropyl-6-methyl-*N*⁴-[tetrahydrofuran-2-ylmethyl]-1,1'-biphenyl-3,4'-dicarboxamide

10 General Method D:

20 A solution of {3'-(cyclopropylamino)carbonyl}-6-methyl-1,1'-biphenyl-4-yl]carboxylic acid (50mg, 0.17mmol) in DMF (1ml) was treated with HATU (65mg, 0.17mmol) at room temperature. After 5 minutes this was added to a solution of the amine (0.17mmol) and HOBt (23mg, 0.17mmol) in DMF (1ml). DIPEA (87 μ l, 3eq) was added. The reaction mixture was left at room temperature for 16 hrs, then concentrated *in vacuo*. The residue was dissolved in DCM (1ml) and loaded onto a SPE cartridge (1g, aminopropyl) which had been pre-equilibrated with DCM. Residual sample was washed on with another portion of DCM (0.5ml). The cartridge was then eluted with: DCM (1x2.5ml), chloroform (1x2.5ml), ethyl acetate (1x2.5ml), and methanol (1x2.5ml). The fractions containing product were isolated by evaporation to give the desired product.

Compound	Amine	MH ⁺	Retention time
Example 15	1-(3-aminomethylbenzyl)pyrrolidine	468	2.48
Example 16	1-(3-aminomethylbenzyl)-4-methylpiperazine	-	2.44
Example 17	4-(aminomethylbenzyl)morpholine	484	2.42

Example 15: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(pyrrolidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 16: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(4-methylpiperazin-1-yl)methyl]biphenyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 17: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(morpholin-4-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 18: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(4-methylpiperazin-1-yl)methyl]biphenyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 19: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(pyridin-4-ylmethyl)-1,1'-biphenyl-3,4'-dicarboxamide

Example 20: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(piperidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 21: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(pyrrolidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 22: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(1H-imidazol-1-ylmethyl)benzyl]-6-methyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 23: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(piperidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 24: *N*³-Cyclopropyl-6-methyl-*N*⁴-[tetrahydrofuran-2-ylmethyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 25: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(pyrrolidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 26: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(4-methylpiperazin-1-yl)methyl]biphenyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 27: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(morpholin-4-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 28: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(4-methylpiperazin-1-yl)methyl]biphenyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 29: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(pyridin-4-ylmethyl)-1,1'-biphenyl-3,4'-dicarboxamide

Example 30: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(piperidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 31: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(pyrrolidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 32: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(1H-imidazol-1-ylmethyl)benzyl]-6-methyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 33: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(piperidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 34: *N*³-Cyclopropyl-6-methyl-*N*⁴-[tetrahydrofuran-2-ylmethyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 35: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(pyrrolidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 36: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(4-methylpiperazin-1-yl)methyl]biphenyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 37: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(morpholin-4-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 38: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(4-methylpiperazin-1-yl)methyl]biphenyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 39: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(pyridin-4-ylmethyl)-1,1'-biphenyl-3,4'-dicarboxamide

Example 40: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(piperidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 41: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(pyrrolidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 42: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(1H-imidazol-1-ylmethyl)benzyl]-6-methyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 43: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(piperidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 44: *N*³-Cyclopropyl-6-methyl-*N*⁴-[tetrahydrofuran-2-ylmethyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 45: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(pyrrolidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 46: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(4-methylpiperazin-1-yl)methyl]biphenyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 47: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(morpholin-4-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 48: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(4-methylpiperazin-1-yl)methyl]biphenyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 49: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(pyridin-4-ylmethyl)-1,1'-biphenyl-3,4'-dicarboxamide

Example 50: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(piperidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 51: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(pyrrolidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 52: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(1H-imidazol-1-ylmethyl)benzyl]-6-methyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 53: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(piperidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 54: *N*³-Cyclopropyl-6-methyl-*N*⁴-[tetrahydrofuran-2-ylmethyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 55: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(pyrrolidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 56: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(4-methylpiperazin-1-yl)methyl]biphenyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 57: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(morpholin-4-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 58: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(4-methylpiperazin-1-yl)methyl]biphenyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 59: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(pyridin-4-ylmethyl)-1,1'-biphenyl-3,4'-dicarboxamide

Example 60: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(piperidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 61: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(pyrrolidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 62: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(1H-imidazol-1-ylmethyl)benzyl]-6-methyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 63: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(piperidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 64: *N*³-Cyclopropyl-6-methyl-*N*⁴-[tetrahydrofuran-2-ylmethyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 65: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(pyrrolidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 66: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(4-methylpiperazin-1-yl)methyl]biphenyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 67: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(morpholin-4-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 68: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(4-methylpiperazin-1-yl)methyl]biphenyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 69: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(pyridin-4-ylmethyl)-1,1'-biphenyl-3,4'-dicarboxamide

Example 70: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(piperidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 71: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(pyrrolidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 72: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(1H-imidazol-1-ylmethyl)benzyl]-6-methyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 73: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(piperidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 74: *N*³-Cyclopropyl-6-methyl-*N*⁴-[tetrahydrofuran-2-ylmethyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 75: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(pyrrolidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 76: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(4-methylpiperazin-1-yl)methyl]biphenyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 77: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(morpholin-4-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 78: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(4-methylpiperazin-1-yl)methyl]biphenyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 79: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(pyridin-4-ylmethyl)-1,1'-biphenyl-3,4'-dicarboxamide

Example 80: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(piperidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 81: *N*³-Cyclopropyl-6-methyl-*N*⁴-[4-(pyrrolidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 82: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(1H-imidazol-1-ylmethyl)benzyl]-6-methyl-1,1'-biphenyl-3,4'-dicarboxamide

Example 83: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(piperidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 84: *N*³-Cyclopropyl-6-methyl-*N*⁴-[tetrahydrofuran-2-ylmethyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 85: *N*³-Cyclopropyl-6-methyl-*N*⁴-[3-(pyrrolidin-1-ylmethyl)benzyl]-1,1'-biphenyl-3,4'-dicarboxamide

Example 86: *N*³-Cyclopropyl-6-methyl-*N*⁴-

Example 18	1-(4-aminomethylbenzyl)-4-methylpiperazine	497	2.42
Example 19	4-aminomethylpyridine	386	2.36
Example 20	1-(4-aminomethylbenzyl)piperidine	482	2.49
Example 21	1-(4-aminomethylbenzyl)pyrrolidine	468	2.45
Example 22	3-(1H-imidazol-1-ylmethyl)aniline	451	2.52
Example 23	1-(3-aminomethylbenzyl)piperidine	482	2.52
Example 24	2-(aminomethyl)tetrahydronan	379	2.85

Abbreviations

DCM	Dichloromethane
DIEA	N,N-Diisopropylethylamine
DME	Dimethoxyethane
DMSO	Dimethylsulfoxide
HATU	O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
HOBT	O-Benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate
PyBOP	1-Hydroxybenzotriazole hydrate
SPE	Benzotriazol-1-yl-oxy-tritylphosphonium hexafluorophosphate
THF	Solid phase extraction
	Tetrahydronan

sodium carbonate (1M, 5ml). The layers were separated and the aqueous layer extracted with ethyl acetate (2x5ml). The organic extracts were washed with brine (10ml), dried (Magnesium sulphate) and concentrated in vacuo to give N-3-(cyclopropyl)-6-methyl-N-4-(piperidin-4-ylmethyl)-1,1-biphenyl-3,4'-dicarboxamide (6mg, 0.020mmol).

NMR: δ H [2 H] - DMSO 8.56,(1H, br), 8.44,(1H, br), 7.92,(2H, d), 7.77,(1H, dd), 7.69,(1H, d), 7.48,(2H, d), 7.39,(1H, d), 3.16,(2H, br), 3.02,(2H, br), 2.84,(1H, m), 2.52,(2H, m), 2.28,(3H, s), 1.22-1.12,(3H, br), 1.75-1.63,(3H, m + br), 0.69-0.52,(4H, 2xm). LC/MS: M^+ 392, retention time 2.26minutes.

Example 25: N3-Cyclopropyl-N4-((5-(dimethylaminomethyl)-2-furylmethyl)-6-methyl-1,1-biphenyl-3,4'-dicarboxamide

5 HATU (65mg, 0.17mmol) was added to a solution of {3'-(cyclopropylcarbonyl)amino}-6'-methyl-biphenyl-4-ylcarboxylic acid (50mg, 0.17mmol) in DMF (1ml). After 5 minutes

HOBT (23mg, 0.17mmol), 2-aminomethyl-5-(dimethylaminomethyl)furan oxalic acid salt (68mg, 0.204mmol) and DIPEA (0.087ml, 0.51mmol) were added and the reaction mixture stirred at room temperature under nitrogen for 18 hours. The DMF was removed *in vacuo* and the residue partitioned between DCM (10ml) and aqueous sodium carbonate (1M, 10ml). The organic phase was reduced to dryness under vacuum and purified by SPE cartridge (SI, 10g) eluting in turn with DCM, ether, ethyl acetate, acetone/nitrile, acetone and ethanol to give the N3-cyclopropyl-N4-((5-

{(dimethylamino)methyl}-2-furyl)methyl)-6-methyl-1,1-biphenyl-3,4'-dicarboxamide (35mg, 0.081mmol).

NMR: δ H [2 H] - DMSO 9.05,(1H, br), 8.43,(1H, br), 7.9,(2H, d), 7.77,(1H, dd), 7.70,(1H, d), 7.48,(2H, d), 7.38,(1H, d), 6.20,(2H, dd), 4.46,(2H, d), 3.36,(2H, s), 2.85,(1H, m), 2.27,(3H, s), 2.12,(6H, s), 0.72-0.52,(4H, 2xm). LC/MS: M^+ 432, retention time 2.31minutes.

The activity of the compounds of the invention as p38 inhibitors may be demonstrated in the following assays:

Example 26: N3-Cyclopropyl-6-methyl-N4-((piperidin-4-ylmethyl)-1,1-biphenyl-3,4'-dicarboxamide

Trifluoroacetic acid (1ml) and 1 drop of water were added to tert-butyl 4-((5-(cyclopropylamino)carbonyl)-2-methyl-1,1'-biphenyl-4-yl)carboxylate (19mg, 0.038mmol) and the solution stirred at room temperature under nitrogen for 1 hour. The trifluoroacetic acid was removed *in vacuo* and the residue partitioned between ethyl acetate (5ml) and aqueous

p38 Kinase Assay

30 The peptide substrate used in the p38 assay was biotin- β -pTSPITTYFFRRR-peptide. The p38 and MEK6 proteins were purified to homogeneity from *E.coli* expression systems. The fusion proteins were tagged at the N-terminus with Glutathione-S-Transferase (GST). The maximum activation was achieved by incubating 20 μ L of a reaction mixture of 30nM MEK6 protein and 120nM p38 protein in the presence of 1.5 μ M peptide and 10nM Mg($^{2+}$ CH₃COO)₂ in 100nM HEPES, pH 7.5, added to 15 μ L of a mixture of 1.5 μ M ATP with 0.08uCl [β -³²P]ATP with or without 15 μ L of inhibitor in 6%DMSO. The controls were reactions in the presence (negative controls) or absence (positive controls) of 50 mM EDTA. Reactions were allowed to proceed for 60 min at room temperature and quenched with addition of 50 μ L of 250nM EDTA and

20

25

33

34

Claims:


1. A compound of formula (I):

mixed with 150 μ L of Streptavidin SPA beads (Amersham) to 0.5mg/reaction. The Dynatech Microfluor white U-bottom plates were sealed and the beads were allowed to settle overnight. The plates were counted in a Packard TopCount for 60 seconds. IC₅₀ values were obtained by fitting raw data to %I = 10^r(1-(I-C2)/(C1-C2)), where I was CRM of background, C1 was positive control, and C2 was negative control.

 α P38 Fluorescence Polarisation Method

α P38 was prepared in house. SB4777790-R Ligand was diluted in HEPES containing MgCl₂, CHAPS, DTT and DMSO. This was added to blank wells of a Black NUNC 384 well plate. α P38 was added to this ligand mixture then added to the remainder of the 384 well plate containing controls and compounds. The plates were read on an LJU Analyst and Fluorescence Anisotropy used to calculate the compound inhibition

15 The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take the form of product, composition, process or use claims and may include, by way of example and without limitation, one or more of the following claims:



5

wherein

X is a bond or a phenyl group which may be optionally substituted; R¹ is selected from an optionally substituted five- to seven-membered heterocyclic ring and an optionally substituted fused bicyclic ring;

R² is selected from hydrogen, C₁-alkyl and -(CH₂)_p-C₃₋₇-cycloalkyl;

or when X is a bond and m and n are both zero, R¹ and R² together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic ring optionally containing one additional heteroatom selected from oxygen and nitrogen, which can be optionally substituted by C₁-alkyl;

R³ is the group -CO-NH-(CH₂)_q-R⁴,

when q is 0 to 2 R⁴ is selected from hydrogen, C₁-alkyl, -C₃₋₇-cycloalkyl, CONHR⁵, phenyl optionally substituted by R⁷ and/or R⁸, heteroaryl optionally substituted by R⁷ and/or R⁸ and heterocyclyl optionally substituted by R⁷ and/or R⁸,

and when q is 2 R⁴ is additionally selected from C₁-alkoxy, NHCOR⁶, NHCNHR⁵, NR⁶R⁹, and OH;

R⁵ is selected from hydrogen, C₁-alkyl and phenyl wherein the phenyl group may be optionally substituted by up to two substituents selected from C₁-alkyl and halogen;

R⁶ is selected from hydrogen and C₁-alkyl;

or R⁶ and R⁹ together with the nitrogen atom to which they are bound, form a five- to six-membered heterocyclic or heteroaryl ring optionally containing up to one additional heteroatom selected from oxygen, sulfur and nitrogen, wherein the ring may be substituted by up to two C₁-alkyl groups;

35

R^7 is selected from C_1 -alkyl, C_1 -alkoxy, -CONR⁹R⁹, -NHCOR⁹, -SO₂NHR⁹, -NHSO₂R⁹, halogen, trifluoromethyl, -Z-(CH₂)_n-phenyl optionally substituted by one or more halogen atom, -Z-(CH₂)_n-heterocycl¹ or -Z-(CH₂)_n-heteroaryl wherein the heterocycl¹ or heteroaryl group may be optionally substituted by one or more substituents selected from C_1 -alkyl;

R^8 is selected from C_1 -alkyl and halogen;

or when R^7 and R^8 are ortho substituents, then together with the carbon atoms to which they are bound, R^7 and R^8 may form a five- or six-membered saturated or unsaturated ring to give a fused bicyclic ring system, wherein the ring that is formed by R^7 and R^8 may optionally contain one or two heteroatoms selected from oxygen, nitrogen and sulfur;

R^9 is selected from hydrogen and C_1 -alkyl;

U is selected from methyl and halogen;

W is selected from methyl and chlorine;

V and Y are each selected independently from hydrogen, methyl and halogen;

Z is selected from -O- and a bond;

m and n are independently selected from 0, 1 and 2, wherein each carbon atom of the resulting carbon chain may be optionally substituted with up to two groups selected independently from C_1 -alkyl, and the sum of $m+n$ is from 0 to 4;

p is selected from 0 and 1;

q and s are selected from 0, 1 and 2;

r is selected from 0, 1 and 2;

or a pharmaceutically acceptable salt or solvate thereof.

25

A compound according to claim 1 wherein R^1 is optionally substituted by up to three substituents selected from C_1 -alkyl, C_1 -alkoxy, oxy, halogen, hydroxyC₁-alkyl, -N(C₁-alkyl)₂, -CH₂-N(C₁-alkyl)₂, -CO₂C₁-alkyl, phenyl optionally substituted by halogen and benzyl optionally substituted by halogen and/or cyano.

30

A compound according to claim 1 or 2 wherein X is optionally substituted phenyl, and R^1 is selected from optionally substituted pyrrolidinyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, tetrazolyl, oxazolyl, oxadiazolyl, piperidinyl, piperazinyl, morpholino, pyranyl, pyridinyl, thienyl, imidazolidinyl, benzimidazolyl and quinolonyl; wherein the optional substituents for R^1 are selected independently from C_1 -alkyl, C_1 -alkoxy, oxy, halogen, hydroxyC₁-alkyl, -N(C₁-alkyl)₂ and -CH₂-N(C₁-alkyl)₂.

35

A compound according to claim 1 or 2 wherein X is a bond, and R^1 is selected from an optionally substituted pyrrolidinyl, isoxazolyl, furyl, thienyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, oxadiazolyl, piperidinyl, piperazinyl, morpholino, pyridyl, tetrahydrofuranyl, tetrahydrothiophenyl and quinolonyl; wherein the optional

36

substituents for R^1 are selected independently from C_1 -alkyl, C_1 -alkoxy, oxy, halogen, hydroxyC₁-alkyl, -N(C₁-alkyl)₂, -CH₂-N(C₁-alkyl)₂, -CO₂C₁-alkyl, phenyl optionally substituted by halogen and benzyl optionally substituted by halogen and/or cyano.

5

A compound according to any one of the preceding claims wherein R^2 is selected from hydrogen, C_1 -alkyl and -CH₂-cyclopropyl.


A compound according to any one of the preceding claims wherein m and n are independently selected from 0, 1 and 2, and the sum of $m+n$ is from 0-3.

A compound according to any one of the preceding claims wherein R^4 is selected from C_1 -alkyl, cyclopropyl, -CH₂-cyclopropyl, pyridinyl and phenyl.

A compound according to claim 1 as defined in any one of Examples 1 to 26, or a pharmaceutically acceptable salt or solvate thereof.


A process for preparing a compound according to any one of claims 1 to 8 which comprises:

20 (a) reacting a compound of formula (XIII)



(XIV)

25 wherein R^1 , R^2 , X , U , W , Y , m , n and r are as defined in claim 1, with a compound of formula (XIV)



(XV)


40

37

38

wherein R⁴ and q are as defined in claim 1,
under amide forming conditions, optionally converting the acid compound (XIII) to an activated form of the acid before reaction with the amine compound (XIV);

5 (b) reacting a compound of formula (XV)



10 wherein R³, U, W, V, Y and r are as defined in claim 1,
with a compound of formula (XVI)



15 wherein R¹, R², X, m and n are as defined in claim 1,

under amide forming conditions;

(c) reacting a compound of formula (XVII)



10

wherein R³, X, U, W, V, Y, m, n and r are as defined in claim 1 and R^{1A} and R^{2A} are R¹ and R² as defined in claim 1 or groups convertible to R¹ and R²,
to give a compound of formula (I).

15 10. A pharmaceutical composition comprising a compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt or solvate thereof, in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.

20 11. A method for treating a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38 kinase comprising administering to a patient in need thereof a compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt or solvate thereof.

25 12. A compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt or solvate thereof for use in therapy.

13. Use of a compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt or solvate thereof in the manufacture of a medicament for use in the

20

39

treatment of a condition or disease state mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38 kinase.

INTERNATIONAL SEARCH REPORT		International Application No
		PCT/EP 02/11573
A. CLASSIFICATION OF SUBJECT MATTER		
IPC 7 A61K31/40 A61K31/417 A61K31/4409 A61K31/453	A61K31/405 A61K31/426 A61K31/495 A61K31/5375 C07D21/26	C07D27/28 C07D295/12 C07D295/18 C07D307/14 C07D307/52
According to International Patent Classification (IPC) or to both national classification and IPC		
B. RELATED SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
IPC 7 A61K C07D		

Documentation searched other than minimum documentation to the extent that such documents are indicated in the fields as searched

Electronic data bases consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Character of document, with indication, where appropriate, of the relevant passages
X	EP 0 849 256 A (JAPAN TOBACCO INC) 24 June 1998 (1998-06-24) page 124 -page 125; claim 1 page 128 -page 130; claim 13 page 130; claim 16
A	WO 00 41698 A (RIEDL, BERND; LOWINGER, TIMOTHY B (JP); DUMAS, JACQUES (US); RENICK, J) 20 July 2000 (2000-07-20) the whole document

<input type="checkbox"/> Further documents are listed in the continuation of box C.	<input checked="" type="checkbox"/> Patent family members are listed in annex.
<p>* Special categories of cited documents:</p> <p>'A' document defining the general state of the art which is not considered to be of particular relevance</p> <p>'B' document which, prior to the priority date of the application, was cited by the examiner as relevant to the international filing date</p> <p>'C' document which may throw doubts on novelty (objection) or which is cited to establish the publication date of another document or other special reasons (as specified)</p> <p>'D' document referring to an own disclosure, use, utilization or other means</p> <p>'E' document published prior to the international filing date but later than the priority date of the application</p> <p>'F' document member of the same patent family</p>	
<p>T' later document published after the international filing date or priority date and not in conflict with the application but which discloses the principle or theory underlying the invention</p> <p>'Y' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>'YY' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is taken alone, but combination with one or more other such documents, such combination being obvious to a person skilled in the art.</p>	

Date of the actual completion of the international search	Date of mailing of the international search report
17 February 2003	26/02/2003

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.O. Box 8000, Prahvallstrasse 2 D-8037 Munich, Germany Telex (851-107) 340-2000, Tx. 951 651 1994, Fax. (851-107) 340-3016	Fink, D

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP 02/11573

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D33/61

According to International Patent Classification (IPC) or to both national classification and IPC
B. PUBLISHERS

Minimum documentation standard (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the file(s) searched

Electronically stored document(s) (name of data base and, where practical, search terms used)

Electronically stored document(s) (name of data base and, where appropriate, of the relevant passage)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category Citation of document with indication, where appropriate, of the relevant passage

Relevant to claim No.

		Patent document cited in search report				Publication data		Patent family member(s)		Publication date	
EP 0849256	A	24-06-1998	AU	0849256 A	19-03-1997						
			EP	0849256 A1	24-06-1998						
			US	6114887 81	16-01-2001						
			NO	9708133 A1	06-03-1997						
			JP	2829539 82	25-11-1998						
			JP	9118658 A	05-05-1997						
			TW	410218 B	01-11-2000						
			US	6420561 81	16-07-2002						
WO 0041698	A	20-07-2000	AU	2725000 A	01-08-2000						
			CA	2389244 A1	20-07-2000						
			EP	11158995 A1	05-12-2001						
			JP	2002534468 T	15-10-2002						
			NO	0041698 A1	20-07-2000						
			US	2002065296 A1	30-05-2002						

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP 02/11573

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D33/61

According to International Patent Classification (IPC) or to both national classification and IPC
B. PUBLISHERS

Minimum documentation standard (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the file(s) searched

Electronically stored document(s) (name of data base and, where practical, search terms used)

Electronically stored document(s) (name of data base and, where appropriate, of the relevant passage)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category Citation of document with indication, where appropriate, of the relevant passage

Relevant to claim No.

		Patent document cited in search report				Publication data		Patent family member(s)		Publication date	
EP 0849256	A	24-06-1998	AU	0849256 A	19-03-1997						
			EP	0849256 A1	24-06-1998						
			US	6114887 81	16-01-2001						
			NO	9708133 A1	06-03-1997						
			JP	2829539 82	25-11-1998						
			JP	9118658 A	05-05-1997						
			TW	410218 B	01-11-2000						
			US	6420561 81	16-07-2002						
WO 0041698	A	20-07-2000	AU	2725000 A	01-08-2000						
			CA	2389244 A1	20-07-2000						
			EP	11158995 A1	05-12-2001						
			JP	2002534468 T	15-10-2002						
			NO	0041698 A1	20-07-2000						
			US	2002065296 A1	30-05-2002						

Name and mailing address of the ISA
European Patent Office, P.O. Box 5010 Patenten 2
NL - 2200 HV Rijswijk
Tel. (+31-70) 340-2040, Tr. 51 651 op nl
Fax: (+31-70) 340-3010

Form PCT/ISA/10 (Second edition) (July 1992)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER: side texts**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.